Browse studies

Find your next paid study

49 recruiting studies matching your filters

MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with intersti…

Pulmonary HypertensionInterstitial Lung Disease (ILD)

Estimated

~$10 – $7,500

Tempus AINCT06911632

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interst…

Pulmonary Hypertension Due to Lung Diseases and HypoxiaPulmonary HypertensionInterstitial Lung Disease

Estimated

~$10 – $1,050

United TherapeuticsNCT06388421

Phase 2

Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease

This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial…

DermatomyositisDermatomyositis Sine MyositisDermatomyositis With Myopathy+4 more

Estimated

~$10 – $6,250

University of MiamiNCT07486869

PRIME-PPF: PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 …

Progressive Pulmonary FibrosisInterstitial Lung Disease

Estimated

~$10 – $750

University of Massachusetts, WorcesterNCT06855329

Phase 2

Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of…

Interstitial Lung Disease Due to Systemic DiseaseScleroderma

Estimated

~$10 – $6,250

Scleroderma Research Foundation, Inc.NCT06195072

Phase 2

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis

Systemic SclerosisSclerodermaInterstitial Lung Diseases

Estimated

~$10 – $7,500

Cabaletta BioNCT06328777

Phase 2

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with oth…

Systemic SclerosisDiffuse Sclerosis SystemicInterstitial Lung Disease+1 more

Estimated

~$10 – $7,500

Paul SzabolcsNCT03630211

Phase 3

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 …

Pulmonary HypertensionInterstitial Lung Disease

Estimated

~$10 – $8,750

Insmed IncorporatedNCT07234032

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibros…

Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease

Estimated

~$10 – $750

Duke UniversityNCT01915511

Phase 2

A Phase 2A, Open-Label Single Arm Multicenter Exploratory Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Doses of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH).

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial L…

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension, Interstitial Lung Disease

Estimated

~$10 – $8,750

AllRock Bio, Inc.NCT07175038

Phase 1

Nucleoside Therapy in Patients With Telomere Biology Disorders

The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology d…

Telomere Biology DisordersDyskeratosis CongenitaRevesz Syndrome+4 more

Estimated

~$10 – $8,750

Suneet AgarwalNCT06817590

Phase 2

Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease …

Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisLung Diseases, Interstitial

Estimated

~$10 – $5,625

National Institute of Environmental Health Sciences (NIEHS)NCT06325696